Fingolimod Medochemie 0.5 mg Cápsula Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

fingolimod medochemie 0.5 mg cápsula

medochemie ltd. - fingolimod - cápsula - 0.5 mg - fingolimod, cloridrato 0.56 mg - fingolimod - genérico - duração do tratamento: longa duração

Fingolimod Fresenius Kabi 0.5 mg Cápsula Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

fingolimod fresenius kabi 0.5 mg cápsula

fresenius kabi pharma portugal, lda. - fingolimod - cápsula - 0.5 mg - fingolimod, cloridrato 0.56 mg - fingolimod - genérico - duração do tratamento: longa duração

Tyruko União Europeia - português - EMA (European Medicines Agency)

tyruko

sandoz gmbh - natalizumab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunossupressores - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 e 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

cloridrato de fingolimode Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

cloridrato de fingolimode

universidade federal do rio grande do norte - cloridrato de fingolimode - agente imunosupressor

MAVENCLAD Brasil - português - ANVISA (Agência Nacional de Vigilância Sanitária)

mavenclad

merck s/a - cladribina - agente imunosupressor

Zeposia União Europeia - português - EMA (European Medicines Agency)

zeposia

bristol-myers squibb pharma eeig - ozanimod cloridrato de - multiple sclerosis, relapsing-remitting; colitis, ulcerative - imunossupressores - multiple sclerosiszeposia is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis (rrms) with active disease as defined by clinical or imaging features. ulcerative colitiszeposia is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

Dimethyl fumarate Mylan União Europeia - português - EMA (European Medicines Agency)

dimethyl fumarate mylan

mylan ireland limited - fumarato de dimetilo - esclerose múltipla remitente-recorrente envio - imunossupressores - dimethyl fumarate mylan is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Dimethyl fumarate Polpharma União Europeia - português - EMA (European Medicines Agency)

dimethyl fumarate polpharma

zaklady farmafarmaceutyczne polpharma s.aceutyczne polpharma s.a. - fumarato de dimetilo - esclerose múltipla remitente-recorrente envio - imunossupressores - dimethyl fumarate polpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Dimethyl fumarate Neuraxpharm União Europeia - português - EMA (European Medicines Agency)

dimethyl fumarate neuraxpharm

laboratorios lesvi s.l. - fumarato de dimetilo - esclerose múltipla remitente-recorrente envio - imunossupressores - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Mitoxantrona Pharmis 2 mg/ml Solução injetável Portugal - português - INFARMED (Autoridade Nacional do Medicamento e Produtos de Saúde)

mitoxantrona pharmis 2 mg/ml solução injetável

pharmis biofarmacêutica, lda. - mitoxantrona - solução injetável - 2 mg/ml - mitoxantrona, cloridrato 2.328 mg/ml - mitoxantrone - genérico - duração do tratamento: longa duração